BrainsWay’s treatment platform is based on a unique breakthrough technology called Deep TMS, which can reach significant depth and breadth of the brain and produce broad stimulation and functional modulation of targeted brain areas.
Deep TMS treatment features unique, patented coils that are fitted into a helmet, which is secured snugly to the patient’s head during the treatment. BrainsWay’s therapy has been utilized in over 60 clinical trials worldwide. In the U.S., the company’s device has been FDA cleared for the treatment of Major Depressive Disorder (MDD) since 2013, FDA cleared (De-Novo) for the treatment of Obsessive Compulsive Disorder (OCD) since 2018, FDA cleared as an aid for short-term Smoking Cessation since 2020, and has now received an expanded indication for Anxious Depression.
“The Brainsway Deep TMS™ System is indicated for the treatment of depressive episodes in adult patients suffering from Major Depressive Disorder who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode.”
“The Brainsway Deep Transcranial Magnetic Stimulation System is indicated to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder.”
“The Brainsway Deep Transcranial Stimulation System is indicated to be used as an aid in short-term smoking cessation for adults.”
“The BrainsWay Deep TMS System is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.”